Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 30

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis62Systemic lupus erythematosus61Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Sjogren's syndrome29Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis15Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+304

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Back pain

Recruiting

Study on Opioid Detoxification Using Buprenorphine, Naloxone, and Oxycodone for Patients with Persistent Spinal Pain Syndrome Type II

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buprenorphine
  • Sponsor:Vrije Universiteit Brussel

Sjogren's syndrome

Recruiting

Study on the Effectiveness of CL-AD-MSC-002 Injections for Dry Mouth in Patients with Sjögren's Syndrome

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cl-Ad-Msc-002
  • Sponsor:Region Hovedstaden

Medical device site joint infection

Recruiting

Study on Antibiotic Treatment for Hip and Knee Joint Infections Using Linezolid, Fusidic Acid, and Rifampicin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fusidic Acid
  • Sponsor:Vaestra Goetalandsregionen

Rheumatoid arthritis

Recruiting

Evaluation of Two Prednisolone Treatment Strategies for Newly Diagnosed, Untreated Rheumatoid Arthritis Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Karolinska University Hospital

Muscle spasticity

Recruiting

Study on the Safety and Effectiveness of IncobotulinumtoxinA for Treating Limb Spasticity in Children with Cerebral Palsy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Juvenile idiopathic arthritis

Recruiting

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Abatacept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Systemic scleroderma

Recruiting

Study on Mesenchymal Stem Cells for Patients with Systemic Sclerosis and Digital Ulcers

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Mesenchymal Stem Cells
  • Sponsor:Universitair Medisch Centrum Utrecht

Osteonecrosis of jaw

Recruiting

Study on the Effects of Pentoxifylline, Retinol Acetate, and DL-Alpha Tocopherol Acetate for Patients with Medication-Related Osteonecrosis of the Jaw

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Centre Hospitalier Et Universitaire De Limoges

Ehlers-Danlos syndrome+4

Recruiting

Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Valsartan
  • Sponsor:Medical University Of Gdansk

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Ocular myasthenia

Not yet recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate25 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.